When was Brain Vectis founded?

Brain Vectis was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is Brain Vectis located?

Brain Vectis is headquartered in Paris, France.

Who is the current CEO of Brain Vectis?

Jerome Becquart of Brain Vectis.

How many employees does Brain Vectis have?

As of Jul 01, 2024, the latest employee count at Brain Vectis is 3.

Is Brain Vectis a funded company?

Brain Vectis is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Sep 13, 2016.

When was the latest funding round of Brain Vectis?

Brain Vectis' latest funding was a $***** Series A round on Sep 13, 2016, with participation from 0 investor. Its primary sector is Genomics. Globally, the Genomics sector has seen $2.84B in funding in 2026 to date.

Where does Brain Vectis rank among its competitors?

Brain Vectis ranks 982nd amongst 1012 active competitors, of which 359 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of Brain Vectis?

Brain Vectis' top competitors include Alnylam, Spark Therapeutics and Denali Therapeutics. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

Brain Vectis - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of gene therapies for the treatment of Alzheimer's and Huntington's disease. It is using AAV to deliver CYP46A1, a key enzyme of brain cholesterol metabolism which is impaired in neurodegenerative diseases. CYP46A1 is reduced in the brain of HD and AD patients. Cholesterol accumulates and the cholesterol pathway is slowed down. CYP46A1 turns the excess cholesterol into a derivative able to move freely from the brain to the blood for peripheral elimination.

Website: brainvectis.com
Social

Key Metrics

Founded Year

2015

Location

Paris, France

Stage

Acqui-Hired

Total Funding

$1.1M in 1 round

Latest Funding Round

Series A, Sep 13, 2016, $*****

Investors

Erganeo

Ranked

982^nd among 1012 active competitors

Employee Count

3 as on Jul 01, 2024

Similar Companies

Alnylam & 1266 more

View Brain Vectis' full profile

Brain Vectis has raised a total funding of $1.1M over 1 round. Brain Vectis has 1 institutional investor.

Here is the list of recent funding rounds of Brain Vectis:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 13, 2016	5320083	Series A	3702324	3457047	1495056	3477507

Access funding benchmarks and valuations. Sign up today!

View details of Brain Vectis's funding rounds and investors

The founders of Brain Vectis are Nathalie Cartier Lacave and Jerome Becquart.

Here are the details of Brain Vectis' key team members:

Nathalie Cartier Lacave: Co-Founder & CSO of Brain Vectis.
Jerome Becquart: Co-Founder & CEO of Brain Vectis.

View details of Brain Vectis's Founder profiles and Board Members

Brain Vectis' employee count trend

Brain Vectis has 3 employees as of Jul 24. Here is Brain Vectis's employee count trend over the years:

Uncover Brain Vectis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Brain Vectis include Alnylam, Spark Therapeutics and Denali Therapeutics. Here is the list of Top 10 competitors of Brain Vectis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
4th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	70/100
5th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
6th	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	70/100
7th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	69/100
8th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
9th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
10th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, Invus & 16 others	68/100
982nd	Brain Vectis 2015, Paris (France), Acqui-Hired	Developer of gene therapies for the treatment of Alzheimer's and Huntington's disease	$1.1M	Erganeo	21/100